AMD Update is our monthly e-newsletter full of the latest information about macular degeneration, treatment and research.
Neurotech Pharmaceuticals announced that the FDA has given them the go-ahead for a Phase 2 clinical trial. The FDA acceptance of the Investigational New Drug Application means that recruitment can begin for their intravitreal implant, using encapsulated cell therapy (ECT).
The development of an eye drop to treat wet AMD has been followed closely. The current therapy of eye injections is expensive and creates a burden on both doctors and patients, as the injections must be repeated frequently. Ohr Pharmaceuticals has been testing its eye drop Squalamine for wet AMD.
When talking about stem cells, people usually think of embryonic stem cells. But, adults carry stem cells in several parts of the body and these can be used as well. According to the National Institutes of Health, the role of adult stem cells in the body is to maintain and repair the tissue in which they are found. Bone marrow, brain and heart are some of the locations.
The standard treatment is for wet macular degeneration involves repeated injections into the eye. These can be very expensive, especially for someone without a secondary insurance. Lucentis and Eylea cost around $2000 per injection. The financial burden can be overwhelming.
The Patient Access Network (PAN) Foundation is dedicated to providing help and hope to underinsured patients who would otherwise be unable to afford high-cost specialty medications.